François Ducray

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi Diagnostic and prognostic markers in gliomas
    François Ducray
    Unité Inserm U842, Service de Neurologie B, Hopital Neurologique, Universite Claude Bernard Lyon 1, Lyon, France
    Curr Opin Oncol 21:537-42. 2009
  2. ncbi Chemotherapy for diffuse low-grade gliomas in adults
    F Ducray
    INSERM U1028, CNRS UMR5292, Service de Neuro Oncologie, Hopital Neurologique, Hospices Civils de Lyon, Lyon Neuroscience Research Center, Neuro oncology and Neuro inflammation Team, 59 Boulevard Pinel, Lyon, France
    Rev Neurol (Paris) 167:673-9. 2011
  3. ncbi Acute headache followed by focal neuropsychological impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
    François Ducray
    Department of Neurology B, Cerebrovascular Unit, Universite Lyon 1, Lyon, France
    J Stroke Cerebrovasc Dis 19:75-6. 2010
  4. ncbi An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
    François Ducray
    INSERM, U842, Lyon, F 69372 France
    Mol Cancer 9:234. 2010
  5. ncbi Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951
    Karima Mokhtari
    Mixed Research Unit, UMR 975, INSERM, National Institute of Health and Medical Research Pierre and Marie Curie University, Pitie Salpetriere Group Hospital, Paris, France
    Cancer 117:3014-26. 2011
  6. ncbi Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status
    François Ducray
    INSERM, Unité U711, Universite Pierre et Marie Curie Paris VI, Paris, France
    J Neurooncol 88:185-8. 2008
  7. ncbi TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors
    Ahmed Idbaih
    INSERM, Unité 711, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Cancer Genet Cytogenet 177:103-7. 2007
  8. ncbi Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas
    François Ducray
    Hopital Neurologique, Service de Neurologie B, Lyon, France
    Eur J Cancer 47:802-8. 2011
  9. ncbi Molecular genetic markers as predictors of response to chemotherapy in gliomas
    Ahmed Idbaih
    INSERM, Unité 711, France
    Curr Opin Oncol 19:606-11. 2007
  10. ncbi Peri-ictal pseudoprogression in patients with brain tumor
    Sylvain Rheims
    Service de Neuro Oncologie, Hospices Civils de Lyon, 59 Boulevard Pinel, 69003 Lyon, France
    Neuro Oncol 13:775-82. 2011

Detail Information

Publications17

  1. ncbi Diagnostic and prognostic markers in gliomas
    François Ducray
    Unité Inserm U842, Service de Neurologie B, Hopital Neurologique, Universite Claude Bernard Lyon 1, Lyon, France
    Curr Opin Oncol 21:537-42. 2009
    ....
  2. ncbi Chemotherapy for diffuse low-grade gliomas in adults
    F Ducray
    INSERM U1028, CNRS UMR5292, Service de Neuro Oncologie, Hopital Neurologique, Hospices Civils de Lyon, Lyon Neuroscience Research Center, Neuro oncology and Neuro inflammation Team, 59 Boulevard Pinel, Lyon, France
    Rev Neurol (Paris) 167:673-9. 2011
    ..The present review focuses on past, recent and ongoing developments in LGGs chemotherapy, including response assessment and potential predictive biomarkers of chemosensitivity...
  3. ncbi Acute headache followed by focal neuropsychological impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
    François Ducray
    Department of Neurology B, Cerebrovascular Unit, Universite Lyon 1, Lyon, France
    J Stroke Cerebrovasc Dis 19:75-6. 2010
    ..We report the atypical presentation of two patients in whom CADASIL was revealed by an episode of headache followed by focal neuropsychological impairment...
  4. ncbi An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
    François Ducray
    INSERM, U842, Lyon, F 69372 France
    Mol Cancer 9:234. 2010
    ..The gene expression (n = 56) and genomic profiles (n = 67) of responders and non-responders to first-line chemotherapy or radiation therapy alone were compared on Affymetrix Plus 2 gene expression arrays and BAC CGH arrays...
  5. ncbi Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951
    Karima Mokhtari
    Mixed Research Unit, UMR 975, INSERM, National Institute of Health and Medical Research Pierre and Marie Curie University, Pitie Salpetriere Group Hospital, Paris, France
    Cancer 117:3014-26. 2011
    ....
  6. ncbi Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status
    François Ducray
    INSERM, Unité U711, Universite Pierre et Marie Curie Paris VI, Paris, France
    J Neurooncol 88:185-8. 2008
    ..This unusual case report suggests that TMZ warrants further investigation in elderly patients with poor performance status...
  7. ncbi TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors
    Ahmed Idbaih
    INSERM, Unité 711, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Cancer Genet Cytogenet 177:103-7. 2007
    ..This suggests no association between oligodendroglial tumors and the SNP in codon 72 of TP53. Similarly, no correlation was found among the TP53 codon 72 polymorphism and prognosis, p53 expression, and chromosomes 1p and 19q status...
  8. ncbi Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas
    François Ducray
    Hopital Neurologique, Service de Neurologie B, Lyon, France
    Eur J Cancer 47:802-8. 2011
    ..1 versus 10.2 months, p=0.0007) and longer OS (124.6 versus 20.6 months, p=0.0001). In conclusion, INA expression is a fast, cheap and reliable prognostic marker, and represents a surrogate marker for 1p19q complete codeletion...
  9. ncbi Molecular genetic markers as predictors of response to chemotherapy in gliomas
    Ahmed Idbaih
    INSERM, Unité 711, France
    Curr Opin Oncol 19:606-11. 2007
    ..This review summarizes recent studies on applications of molecular markers such as chromosome 1p/19q codeletion and MGMT status in the treatment of glioma...
  10. ncbi Peri-ictal pseudoprogression in patients with brain tumor
    Sylvain Rheims
    Service de Neuro Oncologie, Hospices Civils de Lyon, 59 Boulevard Pinel, 69003 Lyon, France
    Neuro Oncol 13:775-82. 2011
    ..This phenomenon is important to recognize in order to avoid futile therapeutic escalation...
  11. ncbi Predictive and prognostic factors for gliomas
    François Ducray
    Hopital Neurologique, Service de Neurologie B, Lyon, France
    Expert Rev Anticancer Ther 11:781-9. 2011
    ..Recently, integrated genomic, transcriptomic and epigenetic studies have unraveled new glioblastoma subgroups that further refines the molecular classification of these tumors. Such an approach should be extended to lower grade gliomas...
  12. ncbi Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas
    Matthieu Peyre
    Hôpital Neurologique de Lyon, 59 Boulevard Pinel, 69677 Bron Cedex, France
    Neuro Oncol 12:1078-82. 2010
    ....
  13. ncbi No association of MDM2 SNP309 with risk of glioblastoma and prognosis
    Soufiane El Hallani
    INSERM, U711, Biologie des Interactions Neurones and Glie, Paris 75013, France
    J Neurooncol 85:241-4. 2007
    ..In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor...
  14. ncbi Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors
    Ahmed Idbaih
    INSERM, Unité 711, Paris, France
    Oncologist 13:978-92. 2008
    ..The integrin inhibitor cilengitide represents another promising strategy...
  15. ncbi New targeted therapies in pituitary carcinoma resistant to temozolomide
    Emmanuel Jouanneau
    INSERM, U1028 CNRS, UMR5292 Lyon Neuroscience Research Center, Neuro oncology and Neuro inflammation Team, 69000, Lyon, France
    Pituitary 15:37-43. 2012
    ..More clinical cases, with mTOR signalling expression analysis of the tumor, must be published before any conclusions can be drawn...
  16. ncbi [What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?]
    François Ducray
    Service de Neurologie B, Hopital Neurologique Pierre Wertheimer, Lyon
    Presse Med 36:1249-54. 2007
    ..These two new treatments are essentially intended for patients younger than 70 years and with a Karnofsky index>70. Ongoing studies are evaluating the possible value of combining these two treatments...
  17. ncbi Delayed onset of a second paraneoplastic neurological syndrome in eight patients
    François Ducray
    Hospices Civils de Lyon, Hopital Neurologique, Centre de Référence Maladie Rare Syndromes Neurologiques Paranéoplasiques, Lyon, France
    J Neurol Neurosurg Psychiatry 81:937-9. 2010
    ..However, recognition of this possibility is important in the management of the patient with PNS...